Skip to main content
Smart Investors Daily
DT

NASDAQ · DTSQ

DT Cloud Star Acquisition Corporation

Financial Services · Financial - Conglomerates

$11.42

Down-$0.06 (-0.52%)

Updated Oct 11, 2026, 6:59 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
97.73M
P/E ratio
29.55
Dividend yield
0.00%
52-week range
$10.26 – $12.90
Volume
333
Avg. volume
12.31K

Price performance · DTSQ

DTSQ price history

1M range · 11 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

DTSQ closed at $11.42 after 11 trading sessions, up 0.18% for the selected period.

Last close
$11.42
Period change
+0.18%
Period low
$11.40
Period high
$11.58
Daily close
View OHLC price history
DTSQ OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$11.4201$11.4201$11.4201$11.4201333
Oct 8, 2026$11.58$11.58$11.42$11.4875.86K
Oct 6, 2026$11.58$11.58$11.58$11.58615
Oct 2, 2026$11.58$11.58$11.58$11.58512
Oct 1, 2026$11.62$11.64$11.55$11.5829.83K
Sep 30, 2026$11.52$11.58$11.52$11.58514
Sep 29, 2026$11.564$11.564$11.52$11.52437
Sep 24, 2026$11.467$11.555$11.40$11.4874.09
Sep 23, 2026$11.563$11.584$11.40$11.5558
Sep 15, 2026$11.40$11.50$11.40$11.50869.21
Sep 14, 2026$11.40$11.4001$11.40$11.40011.22K

Latest DTSQ news

The latest Smart Investors Daily articles mentioning DTSQ.

DTSQ research

Overview

Company profile and research snapshot.

Company profile

DT Cloud Star Acquisition Corp is a blank check company.

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 4, 2026

PrimeGen US, Inc. Announces Proposed Business Combination with DT Cloud Star Acquisition Corporation at an Implied Equity Value of Approximately $1.5 Billion to Advance Its Stem Cell Research and Development Efforts

SANTA ANA, CALIFORNIA, Feb. 04, 2026 (GLOBE NEWSWIRE) -- PrimeGen US, Inc. (“PrimeGen US" or the "Company”), a pioneering biotech company advancing innovative stem cell and exosome therapies, today announced it has entered into a definitive business combination agreement dated as of February 2, 2026 (the "Business Combination Agreement") with DT Cloud Star Acquisition Corporation (“DT Cloud Star”), a publicly traded special purpose acquisition company (Nasdaq: DTSQ). The transaction implies an e

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.